DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
The instant application a Continuation of application 18/299,444 filed 12 April 2023, now Abandoned, which is a Continuation of application 17/839,674 filed 14 June 2022, now U.S. Patent 11,653,969, which is a Continuation of application 17/439,749 filed 15 September 2021, now U.S. Patent 11,399,882, which is a National Stage entry of International application PCT/US21/24514 filed 26 March 2021, which claims the benefit of Provisional U.S. application 63/000,922 filed 27 March 2020.
Status of the Claims
Claims 1-20 are pending, presented for examination, and rejected as set forth below.
Double Patenting - Statutory
A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957).
A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101.
Claims 1-20 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-20 of prior U.S. Patent No. 11,653,969. This is a statutory double patenting rejection.
Double Patenting – Obviousness Type
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-30 of U.S. Patent No. 11,399,882. Although the claims at issue are not identical, they are not patentably distinct from each other because the method of causing hypesthesia of Claims 1-20 represents a broader scope of the methods of alleviating symptoms of ocular surface discomfort encompassed by the claims of the ‘882 patent. While Claims 17-20 of the instant application also encompass the alleviation of ocular surface discomfort set forth by the claims of the ‘882 patent, the claims of the ‘882 patent appear more narrowly directed to specific locations of application of the ice slurry than are encompassed by the instant claims. As the claims of the issued ‘882 patent would anticipate or render obvious the subject matter encompassed by the instant claims if the ‘882 patent represented prior art against the instant application, an obviousness-type double patenting rejection is proper.
Allowable Subject Matter
While no claims are presently in condition for allowance, the claims appear to encompass subject matter free of the art available at the time of the instant applications’ filing. The following is a statement of reasons for the indication of allowable subject matter: The claims encompass the application of a cold slurry to the ocular environment of a subject experiencing ocular discomfort, or of causing hypesthesia (a reduction in ocular discomfort or pain without a complete blockage of ocular sensation – Specification [0070]) in a subject by the application of a composition containing water and a freezing point depressant to the eye of a subject, where the slurry contains at least water and a freezing point depressant, and wherein the application of the cold slurry is one which causes hypesthesia or numbing for a particularly defined period of time, after which sensation is returned to the ocular environment. This language requires that the slurry used in either of the methods of causing hypesthesia of an eye, or of alleviating ocular surface discomfort, be of a sufficiently depressed temperature to induce the hypesthesia or reduction in ocular surface discomfort claimed. The application of this cold slurry is either topically to the surface of the eye or to particularly targeted areas of the ocular environment, either with or without a barrier to the direct application of the slurry to the targeted location. The relief of ocular discomfort by the topical application of cold fluids to the surface of the eye is not per se unknown, as a similar method is taught or suggested by Kim. (U.S. PGPub. 2020/0054483). A chilled fluid, with or without topical active agents, and possibly containing ice crystals, is applied at defined temperatures to the surface of the eye, whereby the cornea or sclera is anesthetized. E.g., [0004-07; 0029; 0032; 0066-67]. Medical ice slurries are likewise known to be effective in providing cryotherapy or therapeutic hypothermia. Garibyan (U.S. PGPub. 2019/0053939 [0004; 0055; 0062]). However, the duration of numbness following cryotherapy is generally understood to be transient. See, e.g., Azza Abdel Moghny Attia & Asmaa Mahfouz Hassan, Effect of Cryotherapy on Pain Management at the Puncture Site of Arteriovenous Fistula Among Children Undergoing Hemodialysis, 4 Intl. J Nursing Sci. 46 (2017) (topical cryotherapy average duration of numbness of 7 minutes), Jane Olson & Vincent Stravino, A Review of Cryotherapy, 52 Phys. Ther. 840, 843 (1972) (rapid return of sensation following discontinuation of cold therapy), and Jenna K Cataldi, et al, Cryotherapy Effects, Part 2: Time to Numbness Onset and Numbness Duration, 18 Int’l. J Athl. Ther. Train. 26, 27 (2013) (post-cryotherapy treatment numbness lasts approximately 5 minutes) (All of record in parent ‘749 application). Applicants claims, by contrast, require the duration of sensation relief over a period of days, not minutes. Applicants disclosure presents evidence which appears to establish that maximum pain relief is achieved between 4-11 days following ocular cryotherapy, with a gradual return to baseline. Given the skilled artisan’s understanding of the duration of numbness, and by extension the relief of discomfort, associated with cryotherapy as is encompassed by the instant claims this is a surprising and unexpected result.
Conclusion
No Claims are allowable.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SEAN M BASQUILL whose telephone number is (571)270-5862. The examiner can normally be reached Monday through Thursday, 5:30 AM to 4 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at (571) 272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SEAN M BASQUILL/Primary Examiner, Art Unit 1614